At #AACR24 , new clinical data demonstrated the promise of therapeutic vaccines for aggressive cancers, including pancreatic and head and neck cancers. Learn more on the #AACRBlog : bit.ly/3TYME8k

Important but less discussed topic #bcsm

Inflammatory breast cancer is a rare, aggressive subtype of #BreastCancer .

Here, our Drs. Rachel Layman, @AnthonyLucci1, Bora Lim, MD and Wendy Woodward MDPhD share how MD Anderson's multi-disciplinary expertise leads to better outcomes for patients with this disease. #BCSM #EndCancer

It is all about balance - great work from Malladi Lab - UTSW #AACR24

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis dlvr.it/T5J2kT

New triple-negative breast cancer models help identify vulnerabilities in chemotherapy-resistant disease.

Our Dr. Amanda Rinkenbaugh shares findings (Abstract 6620) at #AACR24 : brnw.ch/21wIFuM AACR #BreastCancer #EndCancer

The selfie continues - many thought the #pathai was one of key themes- what did you think? #AACR24 Igor Bado Pavlos Msaouel Katie Coleman Dr Choi Dr Sepulveda

I know this wonderful scientist ! Igor Bado #AACR24

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions dlvr.it/T5HbCT

Now Online Fibroblast and myofibroblast activation in normal tissue repair and fibrosis dlvr.it/T5FQMp

Online Now: Enhancer switching in cell lineage priming is linked to eRNA, Brg1’s AT-hook, and SWI/SNF recruitment dlvr.it/T5GtV7

So proud of my Vail AACR buddies Petros Grivas Dr Lipika Goyal #AACR24 discussing how the biomarkers we talk about today impact the changes in treatment of patients. Room 6A now !

Revisit our anniversary focus issue on #cancer !

Read reviews, perspectives, and BenchMarks on the systemic complexity of cancer, and on some of the genes and proteins most intricately involved in the development of the disease.

Explore the issue: cell.com/cell/issue?pii…

“We presented the clinical data showing that saruparib has a very favorable side effect profile, and it also has great drug exposures,” says Dr. Timothy Yap of results from the first-in-human clinical trial PETRA. 

Watch to learn more: bit.ly/43SfsE7 AACR #AACR24 …

Happy selfie with mentors and friends Elizabeth Travis,PhD George W Sledge MD Filip Janku #AACR24

Always good time !

And, of course, I couldn’t leave San Diego without a #BoraSelfie ! Bora Lim, MD

The PARP inhibitor saruparib showed clinical benefit in patients with breast cancer marked by certain DNA repair deficiencies, according to results from the phase I/II PETRA trial, presented by Timothy A. Yap, MBBS, PhD. bit.ly/4atScyK #AACR24 MD Anderson Cancer Center

Science bro MD Anderson Cancer Center discussing ST of GU cancers #AACR24

The #AACR24 ambassador Wafik S. El-Deiry, MD, PhD, FACP interviewing Dr. Kimryn Rathmell on the spot !